Ionis Pharmaceuticals Inc (NASDAQ:IONS)
| 53.38 Delayed Data As of 3:59pm ET |  -0.74 / -1.37%Today’s Change | 39.32 Today|||52-Week Range 73.09 | -11.64% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $7.9B |
Company Description
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Contact Information
Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad California 92010 |
Employees
Shareholders
| Mutual fund holders | 52.95% |
| Other institutional | 32.88% |
| Individual stakeholders | 0.86% |
Top Executives
| Brett P. Monia | Chief Executive Officer & Director |
| Joel Edwards | Vice President-Corporate & Commercial Operations |
| Elizabeth L. Hougen | Chief Financial Officer & SVP-Finance |
| C. Frank Bennett | Chief Scientific Officer |
| Sanjay Bhanot | Chief Medical Officer |
